Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II
Open Access
- 1 September 2021
- journal article
- review article
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 114 (9), 614-619
- https://doi.org/10.14423/smj.0000000000001295
Abstract
The development of immune checkpoint inhibitors (ICIs) has changed the treatment paradigm for cancer. The ICIs nivolumab, pembrolizumab, and cemiplimab target programmed cell death protein 1, and durvalumab, avelumab, and atezolizumab target programmed death ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associated antigen-4. Used as monotherapy or in combination, they have shown...Keywords
This publication has 33 references indexed in Scilit:
- Immune-mediated respiratory adverse events of checkpoint inhibitorsCurrent Opinion in Oncology, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabAnnals of Oncology, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphomaActa Oncologica, 2016
- A Case of Organizing Pneumonia (OP) Associated with PembrolizumabDrug Target Insights, 2016
- Anti–PD-1–Related Pneumonitis during Cancer ImmunotherapyThe New England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaThe New England Journal of Medicine, 2015
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012